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Abstract
Salmonella enterica serovar Typhimurium (S. Typhimurium) infection causes an
inflammatory response through activation of Toll-like receptor 4 by lipopolysac-
charide. Dexamethasone, a glucocorticoid analogue, suppresses inflammatory
responses by many mechanisms including inhibition of the lipopolysaccharide-
induced production of proinflammatory mediators. There is little information on
the effect of glucocorticoids on murine salmonellosis. In this study, we treated
susceptible BALB/c mice by subcutaneous implantation of slow-release dexametha-
sone pellets before infection with S. Typhimurium. Dexamethasone promotes
bacterial growth early in infection and induces a dose-dependent increase in
bacterial growth within mouse livers and spleens. The bacterial load in organs from
infected placebo-treated mice was lower than that in dexamethasone-treated mice.
Glucocorticoids inhibit lipopolysaccharide-induced inflammation partially through
the steroid-inducible protein annexin-A1 (ANXA1). Infection of wild-type and
ANXA1 knock-out mice with S. Typhimurium led to similar organ bacterial loads.
ANXA1 also did not affect the bacterial load in organs from infected dexametha-
sone-treated mice. This suggests that glucocorticoids, independently of ANXA1,
accelerate S. Typhimurium growth in vivo in susceptible BALB/c mice.
Introduction
Infection of mice with Salmonella enterica serovar
Typhimurium (S. Typhimurium) causes a systemic disease
similar to typhoid fever in humans. The initial bacterial
growth rate depends on the genetic background of the mice
and the virulence of the bacterial strain. Systemic infection
with S. Typhimurium results in an initial killing of bacteria,
followed by growth of salmonellae in the liver and spleen
(Mastroeni & Sheppard, 2004). Host control of early bacter-
ial growth depends on the Nramp/SLC11A1 gene and
superoxide production from polymorphoneutrophils. Mice
deficient in superoxide production (Mastroeni et al., 2000)
or those that have the Nramp-susceptible phenotype, such
as BALB/c mice (Fortier et al., 2005), are more susceptible to
infection. In sublethal infection, bacterial growth is con-
trolled after several days such that it reaches a plateau
phase (Mastroeni, 2002). The induction of this plateau
phase depends on the lipopolysaccharide expressed by
S. Typhimurium activating the pathogen-associated mole-
cular pattern receptor Toll-like receptor 4 (TLR4) in macro-
phages. This induces an inflammatory response (Weinstein
et al., 1986; Khan et al., 1998; Royle et al., 2003; Totemeyer
et al., 2005). Lipopolysaccharide-induced activation of
TLR4 yields proinflammatory proteins such as cytokines
(e.g. tumour necrosis factor a) and inducible enzymes [e.g.
inducible nitric oxide synthase (iNOS)] and recruits inflam-
matory cells, the net result of which is granuloma formation
(Muotiala & Makela, 1990; Mastroeni et al., 1991, 1996)
with concomitant control of bacterial growth.
Glucocorticoids have many anti-inflammatory effects,
including downregulation of proinflammatory mediator
production and upregulation of anti-inflammatory pro-
teins. Dexamethasone, a glucocorticoid analogue, blocks
the production of many lipopolysaccharide-induced pro-
inflammatory proteins (Waage & Bakke, 1988; Horton et al.,
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1999; Santini et al., 2001; Korhonen et al., 2002; Li et al.,
2002), inhibits superoxide production in guinea-pig alveolar
macrophages (Maridonneau-Parini et al., 1989) and reduces
cellular migration (Bjornson et al., 1985; Schramm &
Thorlacius, 2003; Edwards et al., 2005). Proinflammatory
rather than anti-inflammatory (IL4, IL10) cytokine produc-
tion is preferentially inhibited by dexamethasone shifting
the host response to lipopolysaccharide from T-helper type
1 (Th1) to Th2 type (Joyce et al., 1996; Franchimont et al.,
1998). This shift in host response is important in mediating
the resolution of inflammation, which, if left unchecked,
would damage the host. Controversially, the use of steroids
at high doses to treat some forms of systemic bacterial
infections is being re-evaluated. Administration of gluco-
corticoids, for example, while maintaining the circulation,
can exacerbate infection (Prigent et al., 2004). Steroid
treatment regimes need to be designed carefully to limit
tissue-damaging inflammatory responses, but not to
enhance infection; therefore, a clear understanding of how
glucocorticoids affect the growth of bacteria in vivo is
required. There is limited published work on the effects of
glucocorticoids on S. Typhimurium infection in vivo. Earlier
work by Hobson (1960) showed that pretreatment of mice
with single high doses of cortisone increased bacteraemia,
increased bacterial proliferation, prevented the plateau
phase and decreased the time to death after intravenous
administration of S. Typhimurium. In chronic murine
salmonellosis, mortality was increased by glucocorticoid
treatment (Plant et al., 1983).
Annexin-A1 (ANXA1) is a glucocorticoid-regulated pro-
tein that is required for some, but not all, the anti-
inflammatory actions of glucocorticoids (Perretti & Flower,
2004). These include the reduction of oedema, a decrease in
polymorphoneutrophil cell migration, inhibition of pyrexia
and inhibition of some of the effects of lipopolysaccharide
(Wu et al., 1995; Perretti & Flower, 2004). N-terminal
peptides of ANXA1 modify the inflammatory responses of
leucocytes (Perretti, 1998) and ANXA1 modulates lipopoly-
saccharide induction of iNOS expression (Wu et al., 1995;
Bryant et al., 1998; Smyth et al., 2006). ANXA1 peptidomi-
metics are under development to treat conditions such as
septic and endotoxic shock, and ANXA1/ mice are more
susceptible to endotoxaemia (Damazo et al., 2005). The effect
of ANXA1 on the host response to infection is unknown.
Glucocorticoids, therefore, inhibit many lipopolysacchar-
ide-induced responses, but studies on the effects of gluco-
corticoids on the progression of Salmonella infections
in vivo are sparse (Hobson, 1960; Katler & Weissmann,
1977). The role of ANXA1 in modifying the host response
to lipopolysaccharides suggests that this protein might
either decrease the inflammatory response of the host
to S. Typhimurium infection or modulate some of the
effects of glucocorticoids during infection. Here, we investi-
gated whether the synthetic glucocorticoid dexamethasone,
when administered chronically to susceptible BALB/c mice,
modified the host response to S. Typhimurium and whether
ANXA1 is important in this process.
Materials and methods
Reagents, cells and animals
Dexamethasone and placebo pellets for implantation were
purchased from Innovative Research of America, Sarasota, FL.
Six- to eight-week-old BALB/c mice were purchased from
Harlan, UK. ANXA1/ and ANXA11/1 mice on a BALB/c
background (Hannon et al., 2003) were a gift from Prof.
R. Flower (Queen Mary College, University of London).
Dexamethasone administration in vivo
All dexamethasone and placebo pellets used were designed
for a 21-day continuous release of dexamethasone (Innova-
tive Research of America). The total dexamethasone content
of the pellets used was 0.5mg or 1.5mg per pellet. These are
equivalent to dose levels of 1.2 and 3.6mg kg1 day1,
respectively, in a 20 g animal. Each animal was subcuta-
neously implanted with one pellet under general anaesthesia
induced by isoflurane (Abbott Laboratories, Queenborough,
UK). Animals were allowed to recover for 2 days before
further procedures were undertaken.
Plasma dexamethasone measurement
The dexamethasone content in plasma was confirmed using
a dexamethasone enzyme immunoassay (EIA) kit according
to the manufacturer’s protocol (Bio-X, Germany), using
dexamethasone diluted in normal mouse plasma to generate
a standard curve.
In vivo S. Typhimurium infection
Salmonella M525P causes a sublethal infection in Nramp-
susceptible mouse stains such as BALB/c and C57Bl/6
(Hormaeche, 1979). M525P was grown statically overnight
in 10mL of Luria–Bertani (LB) broth. Bacteria were
harvested by centrifugation and resuspended in 10mL of
sterile phosphate-buffered saline (PBS). The absorbance was
measured to estimate the CFUmL1. The bacterial suspen-
sion was diluted to 5 103 CFUmL1 in PBS and 0.2mLwas
used to inoculate each animal intravenously (103 CFU per
animal). The bacterial inoculum was plated out on LB agar
and the bacterial number was estimated. Animals were killed
at various time points (4 h–14 days subject to the condition
of mice) after infection, the livers and spleens were removed
and divided for different uses. One organ section was
homogenized in 10mL of sterile water, and appropriate
dilutions were plated onto LB agar plates for viable bacterial
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counts. Organ sections were also either snap-frozen in liquid
nitrogen to isolate total RNA or fixed in 10% formalin for
histological analyses. Blood was collected by a cardiac puncture
into heparinized syringes to prepare plasma samples. Blood
smears were prepared for differential white blood cell counts,
and 200 white blood cells were counted. In a separate study,
mice were infected intravenously with 1 106CFUmL1 of
S. Typhimurium and serial blood samples were taken from the
retrobulbar vein. Blood samples were diluted in sterile water
and plated onto LB agar plates to count viable bacteria. All
mouse studies were conducted in accordance with Home
Office welfare and ethical regulations.
mRNA analyses
iNOS mRNAwas detected by reverse transcriptase (RT)-PCR
using the following oligonucleotides: forward primer, 50-CGC
AGCTGGGCTGTACAA-30; reverse primer, 50-TGATGTTTG
CTTCGGACATCA-30, and probed with 50-CTTCCGGGCAG
CCTGTGAGACCT-30. ANXA1 mRNAwas detected using the
following oligonucleotides: forward, 50-TTTGCCGAGAAGCT
GTACGA-30; reverse, 50-CGAACGGGAGACCATAATCCT-30;
and probe, 50-CCGGAACTCGCCATAAGGCATTGA-30.
mRNA of TLR4, TLR2, MD-2 and 18S RNA gene were quan-
titated by real-time PCR as described (Hormaeche, 1979;
Totemeyer et al., 2003, 2005). All probes were dual labelled
with 50FAM and 30BHQ-1 (Corbett Research, UK). Real-time
RT-PCR was performed and analysed on a RotorGene3000
machine (Corbett Research) with oligonucleotides purchased
from Operon (UK) and probes purchased from Eurogentec
(UK). Fold differences in mRNAvalues were calculated as two
to the power of (40Ct of test) (40Ct of control).
Histology
Liver and spleen samples were fixed in 10% formalin for at
least 24 h. The sections were embedded in paraffin and 5-mm
sections were cut and stained with haematoxylin–eosin. A
Nikon E400 microscope with an eyepiece graticule was used
to count polymorphoneutrophils and macrophages of one
or two serial sections from each tissue (equivalent to an area
of 1.15mm2), the cells being counted under a  20 high
power ( 40 objective). Two separate measurements were
made: the total number of macrophages and polymorpho-
neutrophils per field, and the number of macrophages and
polymorphoneutrophils within recognizable lesions only.
Statistical analysis
Statistical analyses were carried out using PRISM 3.0 (Graph-
pad). Student’s (unpaired) t-test was used for comparison
of two groups. One-way ANOVA (with Dunnet’s post-test
where appropriate) was used for comparison of more than
two groups. Differences were considered to be statistically
significant when Po 0.05.
Results
Effects of dexamethasone on the
haematological profile and spleen weight of
uninfected animals
Plasma levels of dexamethasone were measured by EIA after
implantation of the slow-release pellets. The EIA indicated a
low level of dexamethasone in the serum of placebo-treated
animals (1.59 0.98 ngmL1), presumably due to cross-
reactivity to endogenous cortisone. Dose-dependent levels
of dexamethasone were present, as expected, in animals
that received the dexamethasone implants (0.5 or 1.5mg
per pellet). Dexamethasone levels were elevated above the
baseline level for up to 13 days postimplantation. In infec-
tion experiments, the levels of dexamethasone (ngmL1
mean SD) in infected mice implanted with 0.5mg kg1
pellet were 23.69 20.19 at day 4 (day 6 postimplantation),
13.22 5.13 at day 7 (day 9 postimplantation) and
18.78 13.56 ngmL1 at day 13 (day 15 postimplantation).
In infected mice implanted with the 1.5mg kg1 pellet,
plasma levels of dexamethasone were 76.22 59.63 ngmL1
at day 4 of the infection (day 6 postimplantation). To verify
dexamethasone efficacy, we measured the relative polymor-
phoneutrophil count in blood and spleen size throughout
infection. In blood smears, the relative numbers of blood
polymorphoneutrophils were elevated in dexamethasone-
treated animals (36.0 9.8% for 0.5mg per pellet and
87.3 0.6% for 1.5mg per pellet) compared with placebo-
treated animals (19.0 5.6%) 3 days after pellet implan-
tation. The relative number of circulating lymphocytes
decreased from 78.3 7.6% in placebo-treated mice to
12.3 0.6% in 1.5mg per pellet dexamethasone-treated
animals. Dexamethasone, therefore, induced a classical
haematological profile at both doses used in this study.
Dexamethasone causes a reduction in spleen weight in vivo
(Rooman et al., 1999). Animals that received 0.5 or 1.5mg
dexamethasone per pellet had spleens that were less than
half the weight of the placebo-treated animals 2 days after
pellet implantation (Fig. 1a).
Effects of dexamethasone on the control of
S. Typhimurium infection
In placebo-treated animals, as expected, there was little
growth of S. Typhimurium during the first 4 h of infection
in livers (Fig. 2a) or spleens (Fig. 2b). This initial lag phase
in bacterial growth was reduced in livers from animals
treated with either 0.5 or 1.5mg per pellet dexamethasone
(Fig. 2a; Po 0.001 vs. placebo treated). The bacterial load
was higher in the liver at both doses of dexamethasone in
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comparison with the placebo-treated infected mice (Fig. 2a).
Bacterial load was also increased in the spleen, but this only
reached statistical significance between placebo-treated and
1.5mg per pellet dexamethasone-treated mice on day 4
(Fig. 2b). The dexamethasone-induced bacterial growth rate
slowed between days 1 and 4 in the 0.5mg per pellet-treated
mice, but not in the 1.5mg per pellet-treated mice (Fig. 2b).
The organ bacterial loads for both dexamethasone-treated
groups of animals were significantly higher than the bacterial
load of log 3–log 4CFU per organ observed in placebo-
treated animals on day 4. At the higher dose of dexametha-
sone, mice could not control bacterial growth and therefore
the experiment was stopped in this group of animals. The
bacterial numbers in the mice treated with the 0.5mg per
pellet of dexamethasone started to decrease after day 7,
showing that at this dose of dexamethasone, these mice were
able to control the infection.
To determine whether dexamethasone was affecting
bacterial clearance from the blood on day 1, we measured
the bacterial levels in blood up to 4 h after infecting with
S. Typhimurium. We observed no difference in the bacterial
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Fig. 1. Effect of dexamethasone on the spleen weight of mice. (a)
Spleen weights of mice implanted with placebo, 0.5 or 1.5 mg kg1
dexamethasone pellets 2 days postimplantation (the statistical signifi-
cance compared with the placebo-treated group is indicated by
Po 0.01). (b) Spleen changes in mice implanted (subcutaneously)
with placebo (^) or 0.5 mg per pellet (’) or 1.5 mg per pellet () of
dexamethasone and infected intravenously with 103 bacteria. Spleens
were weighed at regular time points after infection. Data are expressed
as mean weight (g) SD of at least three mice per time point per
treatment, and are representative of two independent experiments.
Statistically significant increases in spleen weights compared with day 0
are indicated by Po 0.05; Po 0.01 and zPo 0.001. Spleen weights
were significantly increased to a similar degree in both the placebo and
the dexamethasone groups of infected mice compared with the unin-
fected mice from day 4 of the infection onwards.
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Fig. 2. Effects of dexamethasone on the growth of Typhimurium in
the liver (a) and spleen (b) of Balb/c mice. Mice were implanted
(subcutaneously) with placebo (^) or 0.5 mg per pellet (’) or 1.5 mg
per pellet () of dexamethasone and infected intravenously with 103
bacteria. Liver or spleen bacterial counts were taken at regular time
points post infection. Data are expressed as the mean CFU per
organ SD of at least three mice per time point, and are representative
of two independent experiments. Statistical significance between
dexamethasone- and placebo-treated mice is indicated on the graph
(Po 0.05; zPo 0.001).
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clearance rate between the placebo-treated mice and those
treated with both doses of dexamethasone. All bacteria had
been cleared from the bloodstream within 4 h of infection
(data not shown) in all mice. A low level of bacteraemia was
observed in mice treated with the 1.5mg of dexamethasone
pellet on day 4 postinfection (mean SD of log 5.3 log
5.2CFUmL1 blood; the large SD is because some animals
had no bacteraemia). No bacteraemia was observed in in-
fected animals treated with the 0.5mg dexamethasone pellet.
Effects of dexamethasone on spleen and liver
infected with S. Typhimurium
Typhimurium induces an inflammatory response in the host
that is associated with splenomegaly. There were no signifi-
cant differences between the spleen weights of infected and
uninfected animals on days 0 and 1 postinfection. Typhi-
murium infection induced splenomegaly in placebo-treated
mice. On days 11 and 14, spleen sizes were 3.1 and 2.9 times
the size of the spleens on day 0 of infection (Fig. 1b).
Although the low-dose dexamethasone pellet (0.5mg)
reduced spleen size by 43 10% before infection, it did not
inhibit S. Typhimurium from inducing splenomegaly (Fig. 1).
In fact, splenomegaly was more pronounced in these mice,
with the mean spleen weights on days 11 and 14 reaching 3.5
and 4.7 times the spleen sizes of placebo-treated mice on day
0. This is equivalent to 7.1 and 9.5 times the mean size of
spleens in the dexamethasone-treated mice before infection.
Typhimurium infection also partially reversed the decrease in
spleen size induced by 1.5mg per pellet dexamethasone
treatment on day 4.
The numbers of polymorphoneutrophils during Typhi-
murium infection were increased in lesions in both the spleen
and the liver on day 4 in all treatment groups (Fig. 3a and b).
More cells were recruited to infected organs in dexametha-
sone-treated groups compared with the placebo group. There
was no difference in the total spleen polymorphoneutrophils
in placebo-treated or either of the dexamethasone-treated
groups, probably because of the large individual variation
within the group (Fig. 3b). Polymorphoneutrophil numbers
in livers up to day 1 were too low for accurate comparison.
However, on day 4, dexamethasone treatment resulted in
an increase in the total polymorphoneutrophils in the liver
in comparison with the infected placebo-treated animals.
In both organs, the number of polymorphoneutrophils
associated with granulomata increased by day 4 (Fig. 3c and
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Fig. 3. Effects of dexamethasone on the
macrophage and polymorphoneutrophil
population in the liver and spleen of mice
implanted (subcutaneously) with placebo
(black bar) or 0.5 mg per pellet (grey bar) or
1.5 mg per pellet (white bar) of dexamethasone
and infected with 103 Typhimurium. (a) Total
polymorphoneutrophils in the liver, (b) total
polymorphoneutrophils in the spleen,
(c) granuloma-associated, polymorphoneu-
trophils in liver, (d) granuloma-associated
polymorphoneutrophils in spleen,
(e) granuloma-associated macrophages in
the liver and (f) granuloma-associated
macrophages in the spleen. Cells were counted
in a 1.15 mm2 field. c, control.
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d). The number of macrophages associated with granulomata
in the spleen and liver also increased in 0.5mg per pellet
dexamethasone-treated animals (Fig. 3e and f). The apparent
lack of increase in macrophage association with granulomata
in the 1.5mg per pellet dexamethasone-treated animals may
be due to the inhibitory effects of high doses of dexametha-
sone on cell migration.
Effects of dexamethasone on gene expression
induced by infection of mice with
S. Typhimurium
Dexamethasone suppresses inflammatory gene expression.
We therefore investigated whether dexamethasone altered
S. Typhimurium-induced proinflammatory gene expression
using quantitative RT-PCR from total liver RNA. In unin-
fected placebo-treated animals, iNOS mRNA was basally
expressed, but basal iNOS expression was suppressed in
dexamethasone-treated mice. Typhimurium infection in-
creased iNOS expression sixfold in placebo-treated mice
between day 1 and day 4 of infection (Po 0.01). A differ-
ential response in iNOS expression was revealed between day
1 and day 4 after infection in dexamethasone-treated mice.
Dexamethasone inhibited both basal and S. Typhimurium-
stimulated iNOS expression at day 1, but by day 4 there was a
significant potentiation in iNOS mRNA expression in re-
sponse to infection (Fig. 4a). The expression of iNOS mRNA
in infected dexamethasone-treated mice was increased by
c. 3.7 106-fold in the 0.5mg per pellet group and by
4.6 106-fold in the 1.5mg per pellet groups from day 1
to day 4.
Glucocorticoids modulate TLR expression; hence, we
investigated whether the elevated iNOS expression observed
on day 4 of infection in dexamethasone-treated mice was
due to enhanced TLR4 expression causing an increased
sensitivity of the mice to S. Typhimurium lipopolysacchar-
ide. Dexamethasone treatment reduced the expression of
TLR4, MD-2 and TLR2 mRNA in uninfected animals in a
dose-dependent manner (Fig. 4b–d). In placebo-treated
animals, the levels of TLR4 mRNA remained relatively
unchanged during infection, but TLR4 mRNA expression
was still decreased in animals of both dexamethasone-treated
groups by day 1 postinfection. By day 4 postinfection, the
levels of TLR4 mRNA in the dexamethasone-treated animals
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Fig. 4. Real-time RT-PCR analyses of iNOS
(a), TLR4 (b), MD2 (c) and TLR2 (d). mRNA levels
in the liver of Typhimurium-infected mice with or
without dexamethasone. Animals were killed
on day 1 (black bar) and day 4 (grey bar)
postinfection. Data are expressed as mean SD
of at least six mice per time point [Ct (cycle time)
subtracted from 40 (the negative end-point)].
Higher values represent higher levels of
mRNA. Statistical significance between
dexamethasone- and placebo-treated mice is
indicated on the graph (Po 0.05; zPo 0.001).
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were the same as those in the placebo-treated infected
animals, indicating that there was a greater increase
in mRNA in dexamethasone-treated animals between
days 1 and 4 than in placebo-treated animals. In the
dexamethasone-treated infected animals, MD2 mRNA levels
decreased on day 1 postinfection, but were subsequently
restored to levels similar to those of the infected placebo-
treated animals. TLR2 mRNA levels were decreased transi-
ently by both doses of dexamethasone in uninfected
animals. Infection enhanced TLR2 mRNA in all groups of
mice by day 4. The upregulation in TLR4, MD-2 and TLR2
mRNA by day 4 of S. Typhimurium infection coincides with
the upregulation of iNOS mRNA and with the influx of
inflammatory cells into the liver. Inflammatory cell influx
into the liver is likely to account for some, but not all, the
changes in gene expression that we observed (Totemeyer
et al., 2003, 2005).
Effects of ANXA1 on the host response to
S. Typhimurium infection in the presence or
absence of dexamethasone
ANXA1/ and ANXA11/1 mice were injected intrave-
nously with log 3 CFU of S. Typhimurium strain M525P or
PBS. The S. Typhimurium growth rates were identical in
both ANXA11/1 and ANXA1/ mice strains (Fig. 5),
indicating that ANXA1 does not influence the host immune
response to S. Typhimurium infection. When ANXA11/1
and ANXA1/ animals were implanted with either placebo
or 1.5mg dexamethasone pellets, and subsequently infected
with S. Typhimurium, bacterial growth was enhanced by
dexamethasone to a similar extent in both strains of mice
(Fig. 5). Spleens from both strains of uninfected mice were
similar in weight. The effects of dexamethasone on spleen
weight in both uninfected and infected mice were indepen-
dent of ANXA1 (data not shown). Dexamethasone, there-
fore, had similar effects on S. Typhimurium infection in
both ANXA11/1 and ANXA1/ mice, suggesting that
ANXA1 is unlikely to be important in mediating the effects
of glucocorticoids during the early phase of this infection.
Discussion
In this study, we found that the synthetic glucocorticoid
analogue, dexamethasone, dose dependently suppressed
the ability of susceptible mice to control S. Typhimurium
infection. Glucocorticoids suppress inflammation, and an
inflammatory response to S. Typhimurium is critical for the
successful control of bacterial growth (Khan et al., 2001).
The glucocorticoid-inducible protein ANXA1 mediates
some, but not all, the anti-inflammatory effects of gluco-
corticoids (Flower, 1990). Here, ANXA1 had no effect on
S. Typhimurium infection in the presence or absence
of glucocorticoids. Studies in ANXA1/ mice show an
important role for ANXA1 in protecting animals against
the effects of inflammation and systemic lipopolysaccharide
administration (Hannon et al., 2003; Damazo et al., 2005),
and ANXA1/ macrophages show deficits in phagocytic
activity in vitro (Yona et al., 2004). Lipopolysaccharide
activation of TLR4 plays a key role in driving the protective
immune response against S. Typhimurium infection (Wein-
stein et al., 1986; Royle et al., 2003; Totemeyer et al., 2003;
Weiss et al., 2004). We, therefore, expected ANXA1/mice
infected with S. Typhimurium to show an altered response
to infection with S. Typhimurium in vivo. ANXA1 also did
not play a role in mediating the effects of dexamethasone on
S. Typhimurium infection in our study. This suggests a
differential effect of ANXA1 on inflammation induced by
lipopolysaccharide and infection with S. Typhimurium.
While this is unexpected, given the importance of lipopoly-
saccharide in driving a protective immune response against
S. Typhimurium infection, perhaps it is not so surprising,
given the range of other bacterial factors, such as bacterial
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Fig. 5. Growth of Typhimurium in the spleen (a) and liver (b) of ANXA1/1
(square) and ANXA1/ (circle) mice with (open) or without (filled)
dexamethasone treatment. The data are mean SD of at least three
animals per time point.
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proteins, that modify host inflammatory signalling, pro-
duced by Salmonella species. Our data suggest that ANXA1
plays no role in the pathogenesis of infection and it may be
that peptides based on ANAX1 could therefore be useful
immunomodulators in infected patients.
Dexamethasone, as expected, had a marked effect on
S. Typhimurium infection in vivo. The increased growth of
S. Typhimurium seen in dexamethasone-treated animals is
consistent with earlier studies conducted by Hobson in 1960
using single bolus injections of cortisone in different strains
of mice infected with S. Typhimurium (Hobson, 1960).
Here, we used dexamethasone as a slow-release implant
to minimize the handling of animals and the consequent
stress-induced release of endogenous glucocorticoids.
Administration of dexamethasone via subcutaneous implants
produced a classical steroid profile in the mice, including
neutrophilia and a reduction in spleen weight. Our data show
that dexamethasone dose dependently increases bacterial load
by day 1 of infection. Dexamethasone suppresses the produc-
tion of many inflammatory proteins including TNFa (Ogawa
et al., 2005) and iNOS (Korhonen et al., 2002). Suppression of
TNFa, IFNg, iNOS, IL-12 or IL-18 increases the host suscept-
ibility to S. Typhimurium (Nauciel & Espinasse-Maes, 1992;
Mastroeni, 2002), but these proteins are not involved in
controlling the initial bacterial growth rate. The initial killing
of S. Typhimurium is mainly driven by nicotinamide adenine
dinucleotide phosphate oxidase (phox) and Nramp activity
(Mastroeni, 2002). Dexamethasone does not affect the
expression of cytochrome b-245 (p22-phox) (Ogawa et al.,
2005), but does suppress phagocytic oxidative burst activity
(Roshol et al., 1995). Cortisone enhances the growth of
mycobacteria in macrophages and suppresses Nramp expres-
sion in susceptible mice, such as the BALB/c strain used in
this study (Brown et al., 1995). To determine the precise
mechanism of how corticosteroids affect S. Typhimurium
growth in vivo, more experiments need to be performed,
particularly comparing mouse strains with functional and
nonfunctional Nramp, to determine the importance of phox
activity in the dexamethasone-induced increase in the bacter-
ial growth rate.
Bacterial growth was controlled after day 7 postinfection
in 0.5mg dexamethasone-treated animals, and bacteria
started to be cleared. The check in bacterial growth is unlikely
to be due to a decline in the serum dexamethasone level
because this did not occur until after day 11 of the infection
and the biological half-life of dexamethasone can be as long as
48h. At the higher dose of dexamethasone, no check in
bacterial growth was apparent, but this is because the high
bacterial load seen in these animals led to an early termi-
nation of the experiment. Our observations suggest that
dexamethasone either may not inhibit or only has an effect
at high doses on the bacterial clearance mechanisms involved
in the later stages of infection.
Dexamethasone alters the distribution of leucocytes and
prevents the induction of many chemokines and, therefore,
we were interested in how dexamethasone might influence
the host response to infection. Dexamethasone increased the
total numbers of polymorphoneutrophils and macrophages
profoundly in animals infected with S. Typhimurium by day
4 of infection. The polymorphoneutrophil count increased
in a dose-related manner, and this is probably associated
with the direct effect of dexamethasone on polymorphoneu-
trophil migration and with the increased bacterial burden
seen in infected animals with increasing doses of the drug.
The liver of infected animals treated with the highest dose of
dexamethasone showed that the bacteria were present not
only in polymorphoneutrophils and macrophages but also
in hepatocytes, again probably due to the increased bacterial
load in these animals. Dexamethasone suppresses lipopoly-
saccharide-induced polymorphoneutrophil and macrophage
migration (Perretti, 1998), but does not appear to suppress
polymorphoneutrophil migration into lesions in response to
S. Typhimurium infection in vivo.
The suppression of inflammatory gene expression by
glucocorticoids is well known and, indeed, we showed iNOS
mRNA suppression by dexamethasone in uninfected animals.
Yet, in our study, by day 4 of infection S. Typhimurium-
induced iNOS mRNA expression was greater in dexametha-
sone-treated animals than in the placebo-treated mice. This
was accompanied by enhanced upregulation in mRNA
for TLR4, MD-2 and TLR2 (proteins that mediate lipopoly-
saccharide-induced iNOS transcription) in dexamethasone-
treated mice in comparison with placebo-treated animals.
Glucocorticoidsmodulate TLR expression, although precisely
how this occurs is unclear. Sakai et al. (2004) reported that
TLR2 expression in epithelial cells is enhanced by dexametha-
sone, and speculated that dexamethasone enhances the host
defence against bacterial infection by upregulating TLR2.
Ogawa et al. (2005) found no evidence for the glucocorticoid
regulation of TLR expression, whereas Rozkova et al., (2006)
showed enhanced TLR2 and TLR4 expression accompanied
by decreased dendritic cells maturation in patients treated
with high levels of glucocorticoids. Dexamethasone reduces
inflammatory cytokine production from peripheral blood
mononuclear cells infected with Streptococcus pneumoniae or
Neisseria meningitidis by inhibiting the activation of the
transcription factor nuclear factor kB, but glucocorticoid
does not affect the increased mRNA stability induced by
bacterial infection (Mogensen et al., 2008). Here, we mea-
sured TLR expression in the whole organ over a long course
of time. It is quite likely that our results are complicated by
the presence of many cell types within the liver with a
differential sensitivity to regulation by glucocorticoids and
also by the opposing effects of dexamethasone and bacteria
on gene mRNA transcription and stability, respectively.
The differences we see in TLR levels and iNOS transcription
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in response to dexamethsone in vivo therefore need further
investigation.
In conclusion, the glucocorticoid analogue dexametha-
sone suppresses the ability of the susceptible mice to control
S. Typhimurium infection, particularly at the early innate
resistance phase, suggesting that this compound is inducing
defects in the cellular bacterial killing mechanisms. The
effects of glucocorticoids are independent of ANXA1, sug-
gesting that while this protein modulates some of the effects
of exogenously administered lipopolysaccharide, it does not
affect the host response to infection with S. Typhimurium.
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